Understanding the determinants of the host innate immune response to systemic administration of adenoviral (Ad) vectors is critical for clinical gene therapy. Acute toxicity occurs within minutes to hours after vector administration and is characterized by activation of innate immune responses. Our data indicate that in mice, indicators of vector toxicity include elevations of cytokine levels, liver transaminase levels and thrombocytopenia. To discern potential targets for blunting this host response, we evaluated genetic factors in the host response to systemically administered first-generation Ad vectors (FGV) and helper-dependent Ad vectors (HDV) containing b-galactosidase expression cassettes. A preliminary screen for modulation of vector-induced thrombocytopenia revealed no role for interferon-g, mast cells or perforin. However, vector-induced thrombocytopenia and interleukin 6 (IL-6) expression are less evident in tumor necrosis factor alpha (TNFa)-deficient mice. Moreover, we also demonstrated that TNFa blockade via antibody or huTNFR:Fc pretreatment attenuates both thrombocytopenia (440% increase in platelet count) and IL-6 expression (480% reduction) without affecting interleukin 12 , liver enzymes, hematological indices or vector transduction in a murine model. Our data indicate that the use of HDV, in combination with clinically approved TNFa immunomodulation, may represent an approach for improving the therapeutic index of Ad gene therapy for human clinical trials.
Introduction
Adenoviral (Ad) vectors represent an attractive candidate for gene therapy for a variety of diseases, owing to large transgene carrying capacity and high-level transduction of several cell types. Ad vectors can be distinguished between early generation vectors (most viral genes intact) vs helper-dependent Ad vectors (HDV) (viral genes deleted) depending on whether viral coding sequences remain. 1 Systemic administration of Ad vectors in immunocompetent recipients induces a multiphasic toxicity profile. Immediate-early cytotoxicity can occur within minutes, is vector transcription-independent and is mediated in part by viral particle interaction with components of the host innate immune response. 2 This phase is characterized by acute production of proinflammatory cytokines which bears similarity to the early phases of sepsis, a hyperinflammatory response to infection. 3 Intermediate-early toxicity is characterized by an augmentation of this response and includes hepatotoxicity, coagulopathy and further amplification of inflammatory cytokines and chemokines, and may last for hours to days after vector application. 4 As a proinflammatory cytokine, tumor necrosis factor alpha (TNFa) is heavily implicated in the initiation and progression of autoimmune inflammatory disorders. 5, 6 However, its role in Ad-induced toxicity has not been extensively studied. Although some studies found no elevation of TNFa following Ad injection, [7] [8] [9] [10] other studies have found that TNFa release is in fact a consequence of higher-dose vector application in mice and nonhuman primates. 4, 8 Furthermore, low levels of circulating serum TNFa may not reflect membranebound TNFa in the tissues. 10 Indeed, proinflammatory cytokines such as TNFa may demonstrate an immediate peak (corresponding to host/vector interaction) followed by a second peak corresponding to the host response to Ad gene transcription.
These early, innate immune phases of toxicity are followed by chronic toxicity, which corresponds to a transition to the adaptive immune response and is induced in part by persistent expression of viral genes and/or transgene. As HDV is devoid of viral genes, it elicits an attenuated adaptive immune response compared to first-generation adenoviral vector (FGV). [12] [13] [14] Nevertheless, stimulation of the host innate immune response remains a major challenge, limiting the effective translation of HDV-mediated gene transfer in humans. 2 Systemic administration of recombinant Ad vectors has been associated with dose-dependent platelet reduction (thrombocytopenia) in different animal models 4, 15, 16 and human patients. 17 Of note, mild thrombocytopenia is also among the typical manifestations of naturally occurring wild-type Ad infection. 18 A severe albeit transient drop in platelet counts may reflect an increased risk, or early sign, of disseminated intravascular coagulation that can lead to potentially fatal multiorgan failure. 10 The exact mechanism of the development of thrombocytopenia after recombinant Ad vector administration has not yet been extensively investigated. Although one group found no direct interactions between Ad particles and human platelets in vitro, 19 another group demonstrated transduction of megakaryocytes (platelet precursors) by Ad. 20 Direct damage or activation of intravascular endothelial cells with subsequent platelet sequestration by the reticuloendothelial system has been proposed. 4, 16 The time course for thrombocytopenia for HDV vs FGV systemic treatment has not been fully addressed.
In mammals, several nonredundant immune pathways contribute to rapid clearance of pathogens. However, these pathways may become dysregulated, such as the uncontrolled amplification of the immune response seen in sepsis. 3 Similarly, Ad vectors have induced excessive, lethal innate immune responses in baboons and in a human. 10, 21 We have therefore attempted to identify critical innate defense mechanisms employed in response to Ad vectors. Identification and transient modulation of relevant immune pathways may improve the therapeutic and toxic profiles of Ad vectors. To identify potential therapeutic target pathways, we evaluated the toxicological response of various immunodeficient mice.
As cytokine stimulation is an early response to systemic Ad, we evaluated key cytokines such TNFa and interferon-g as genetic determinants in Ad-mediated acute toxicity. 22, 23 It is known that TNFa works both as a proinflammatory cytokine and as an effector of cytolysis of TNF receptor-bearing cells, leading to elimination of Ad-transduced cells. 24 Furthermore, TNFa is critical for maturation and migration of antigen presenting cells to the lymph nodes, where they activate T and B cells. It has been shown that in TNFa-deficient mice, dendritic cell maturation in response to systemic injection of Ad vector is impaired. 25 Furthermore, there is direct evidence that activation of platelet caspases induced by TNFa causes thrombocytopenia. 26, 27 Here, we examine the role of TNFa in the development of acute and intermediate toxicity associated with systemic administration of Ad vectors. Based on the many studies validating the use of anti-TNFa therapy for disorders of inflammation 5 such as rheumatoid arthritis, psoriasis and Crohn's disease, [28] [29] [30] we also tested antiTNFa treatment as a palliative measure against Adinduced host inflammatory responses.
Results

Kinetics of Ad-induced thrombocytopenia
HDV have demonstrated an improved toxicity profile compared to early generation Ad vectors. 13 Although FGV causes elevation of liver enzymes in the serum (which is indicative of hepatic tissue damage), a previous mouse study using 1 Â 10 13 vp/kg of HDV demonstrated no significant increases in the liver enzymes alkaline phosphatase, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) by 72 h after injection. 12 In another study, however, significant elevations of liver enzymes were found at 1 day after HDV injection. 13 The identical enzyme elevations caused by both FGV and HDV in that study reinforce the concept that earlier toxicity is provoked by Ad capsids and not by viral transcription. Systemic injection of FGV as well as HDV has also been associated with acute, dose related, transient thrombocytopenia. 31 In order to evaluate possible differences in the early kinetics of thrombocytopenia, we injected equal doses of a FGV or HDV into C57BL6/J mice. Groups of five mice were treated with one of the following: saline solution, FGV at 1.5 Â 10 12 vp/kg or HDV at 1.5 Â 10 12 vp/kg. Mice in each group were bled and terminally killed at 3, 12 or 72 h after vector administration. A comparable reduction in platelet counts was observed in both Ad-treated groups beginning at the early experimental time point of 12 h (Figure 1a) . By 72 h, platelet number was reduced by 440% in both FGV-and HDV-treated animals, depressing platelet count below the normal range ( Figure 1a ). Platelet number was generally restored by 1 week after injection (data not shown). We also observed a transient leukopenia in both FGV-and HDV-treated mice ( Figure  1b) , which is consistent with previous mouse studies 32 but contradictory to baboon data. 21 Analysis of serum ALT levels revealed a steady increase in mice treated with FGV, consistent with previous reports. 12, 13, 21 Conversely, in animals treated with HDV an early increase of ALT was quickly resolved to normal levels by 12 h of administration ( Figure 1c ). This suggests that continued liver injury caused by FGV is a consequence of viral gene expression, and is absent after administration of viral gene-deleted HDV. 13 
Effect of Ad on platelets in vitro
We assayed the platelet phenotypic changes brought about by exposure to Ad in vitro. One marker of platelet activation is the conformational change of the platelet integrin receptor a IIb b 3 , which is able to recognize RGD motifs. Theoretically, the RGD motif of the Ad penton protein may interact with the a IIb b 3 receptor; 19 receptor activation can be assessed via fluorescence-activated cell sorting (FACS) using a fluorescent PAC-1 antibody specific for the activated form of a IIb b 3 . Owing to the prohibitive amount of mice required for adequate blood collection, we conducted in vitro experiments using human platelet samples.
Human platelets, 4.5 Â 10
6
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Ad-induced thrombocytopenia in immunodeficient mouse strains
Systemic injection of Ad vectors has been associated with acute thrombocytopenia. 15 Intravenous (i.v.) Ad administration in mice also leads to activation of dendritic cells, macrophages, complement and mast cells 8 with subsequent release of different proinflammatory cytokines triggering an acute response to the vector. 33 A key regulator in this process is NFkB which activates several cytokines, including TNFa and interferons. In addition, a role for the perforin pathway in the T-cell-mediated antigen-specific response against Ad vectors has been proposed. 24 In order to determine the impact of different immune effectors on Ad-induced acute toxicity, we used several strains of mice deficient for various components of the innate immune response.
As a preliminary screen for the role of cytokines, granule release and perforin as potential modifiers of Ad-induced thrombocytopenia, we administered FGV i.v. into TNFa-, interferon-g-, mast cell-or perforindeficient mouse strains on the B6 genetic background. Platelet counts were measured 72 h after administration. No significant difference in the levels of circulating platelets was observed in interferon-g deficient, mast cell deficient or perforin-deficient mice compared to wildtype platelet counts (data not shown).
In contrast, TNFa-deficient mice revealed a significantly reduced thrombocytopenia compared to wild-type mice in response to systemic administration of Ad. Whereas the reduction in platelet number was vector dose-dependent in TNFa-deficient mice as well as wildtype mice, platelet counts in TNFa mice were approximately 40-50% higher than the wild-type values at all experimental doses (Figure 3) . A similar difference between wild-type and TNFa-deficient platelet counts was observed after injection with either FGV or HDV at equivalent doses ( Figure 3 ). This suggests that intravascular administration of Ad vector induces acute thrombocytopenia via a TNFa-mediated pathway that is independent of viral gene expression.
Ad-induced IL-6 in TNFa null and TNFa-depleted animals
Interleukin-6 (IL-6) is a proinflammatory cytokine whose expression is substantially increased by various pathogenic and physiologic insults. 34 Administration of Ad vectors causes a rapid induction of IL-6 in mice, primates and humans, 10, 35, 36 indicating that IL-6 is a marker of the innate immune response to Ad administration.
We evaluated IL-6 levels following systemic vector administration in TNFa-deficient and wild-type mice. At 6 h after treatment with 5 Â 10 12 vp/kg FGV, the mice displayed a vector-induced increase in IL-6 levels in both wild-type and TNFa-deficient mice (Figure 4a ). However, IL-6 levels in TNFa-deficient animals (10.6672.89 pg/ ml) were significantly lower than in wild-type mice (53.65716.6 pg/ml). These results suggest that the rapid, steep increase of IL-6 levels after systemic Ad vector administration is partially dependent upon a TNFamediated response.
We also explored the possibility of modulating the IL-6 response against Ad by blocking TNFa. Treatment with specific antimurine TNFa antibodies before systemic administration of 5 Â 10 12 vp/kg of FGV reduced the TNFa-mediated IL-6 response against the vector by more than fivefold (Figure 4b ). The magnitude of IL-6 attenuation in antibody-pretreated animals was equivalent to that seen in TNFa-deficient mice (Figure 4a ), suggesting that our antibody pretreatment dose provides an accurate phenocopy of genetic TNFa deficiency. However, neither proinflammatory interleukin 12 (IL-12) cytokine levels (Figure 4c) , b-galactosidase transgene activity (Figure 4d ) or X-gal staining of liver (data not shown) was altered by anti-TNFa antibody treatment.
Serum TNFa levels were measured by enzyme-linked immunosorbant assay (ELISA) but were below the sensitivity of the assay (3 pg/ml) in Ad-infected mice irrespective of anti-TNFa antibody pretreatment (data not shown).
Effect of anti-TNFa antibody on vector-induced thrombocytopenia
Importantly, the anti-TNFa antibody pretreatment also partially protected the animals from the severe thrombocytopenia seen 3 days after injection, demonstrating a 46% increase in platelet count compared to nonpretreated animals (Figure 5a ). This finding further establishes a partial role for the TNFa signaling pathway in the initiation and amplification of vector-induced thrombocytopenia. It should be noted, however, that platelet levels in both Ad-treated groups, irrespective of antibody pretreatment, were below the normal range. Seventy-two hour increases in leukopenia and serum liver enzymes, consequences of viral infection, were unaffected by antiTNFa antibody pretreatment (Figure 5b and c) , as was transgene activity (Figure 5d ). 
Modulation of
TNFa, associated with systemic delivery of FGV and HDV VP Mane et al
Usage of a clinically approved anti-TNFa drug
To determine potential clinical applicability of anti-TNFa therapy, we studied the efficacy of an FDA approved drug (huTNFR:Fc) composed of a human TNFa receptor fragment fused to the immunoglobulin Fc region (Amgen, Thousand Oaks, CA, USA). This compound has previously shown efficacy in murine models of inflammation. 37, 38 Compared to animals receiving 2 Â 10 12 vp/ kg of FGV alone, 434% increase in platelet count (similar to that observed using anti-TNFa antibody pretreatment) was observed in mice pretreated with huTNFR:Fc 24 h before vector administration ( Figure 6 ). Pretreatment In a separate experiment, huTNFR:Fc pretreatment blocked Ad capsid-induced IL-6 production to a degree similar to anti-TNFa antibody pretreatment (data not shown).
These studies suggest that huTNFR:Fc may have multiple effects on diverse cell types including platelets. A version of huTNFR:Fc is currently available for clinical use as the FDA-approved drug Enbrel s or etanercept (Amgen, Thousand Oaks, CA, USA), for the treatment of symptoms of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis. 30 Based on the pharmacological data available, huTNFR:Fc doses used in this study are well tolerated in humans. 5 
Discussion
Toxicity associated with systemic Ad vector administration is the result of a multiphasic process. 4 Acute toxicity is related to viral interaction with target cells and consequent vector entry with viral uncoating. These events in the Ad infectious cycle may occur rapidly in vivo within minutes to hours of vector administration. This phase is not triggered by active expression of transgene or viral genes since treatments that compromise transcription, such as psoralen-mediated UV Adgenome deactivation, do not attenuate acute toxicity. 9 Moreover, empty viral capsids (having no genomic DNA inside) were shown to induce a substantial release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro. 39 In support of the viral geneindependent development of acute toxicity, our data correlate with recent studies that show that HDV have similar acute toxicity profiles as FGV. 2, 13, 21 Intermediate toxicity is less well defined and likely involves de novo cellular transcription and amplification of cytokine release. We demonstrate that HDV has a safer profile than FGV with regard to liver transaminases (Figure 1c) , suggesting that some intermediate toxicities occurring after injection are associated with viral gene transcription. Data from baboons and humans have demonstrated that acute vector induction of cytokines may be indicative of fulminant inflammation and coagulopathy, which can be fatal. 10, 21 In these reports, lethal outcomes preceded the antigen-specific adaptive immune response. Therefore, acute and intermediate toxicity must be reduced to acceptable levels before persistent and tolerable vector transgene expression can be achieved. Factors which may influence the innate immune response to Ad vectors include magnitude of cytokine response, route of administration and dose.
Delayed chronic toxicity arises several days after Ad administration. It is mediated by the host adaptive immune response to de novo production of antigens. 25 In early generation Ad vectors, the primary antigens derive from viral gene products although potential neoantigenicity of the therapeutic transgene may also contribute; 40 with HDV, however, no viral gene products are made. Nevertheless, significant acute toxicity remains an obstacle to clinical application of HDV. 2 To that end, we have attempted to identify critical innate immune effector molecules, whose downmodulation might attenuate vector-induced acute toxicity, thereby increasing the therapeutic index of treatment.
We identified TNFa as a cytokine whose genetic deletion led to improvements in vector-induced acute toxicities, specifically thrombocytopenia (436% platelet increase) and IL-6 expression (480% reduction). Interestingly, pretreatment with TNFa-antagonist antibody or huTNFR:Fc recapitulated the mitigated thrombocytopenia and IL-6 levels of TNFa null mice, as compared to wild-type mice. However, several other parameters (IL-12, WBC, ALT and transgene expression) were unaffected, which underscores the limitations and specificity of anti-TNFa treatment as well as the complexity of the innate response and the involvement of multiple parallel signaling pathways.
The use of huTNFR:Fc pretreatment in vivo is significant because a version of this drug is already approved for clinical use, potentially facilitating its inclusion as a prophylactic measure against inflammation and thrombocytopenia in Ad gene therapy trials. Of note, huTNFR:Fc was administered at a dose currently indicated in humans.
Our in vitro experiments demonstrate direct interactions between platelets and Ad. Although these results are in apparent contradiction to those of Eggerman et al., 19 these discrepancies are likely due to large differences in Ad:platelet ratios between studies. Furthermore, that study assessed platelet aggregation but not activation. A precedence for direct interaction has also been established by an Ad megakaryocyte transduction study. 20 Various strategies have been attempted in order to reduce or eliminate the acute toxicity associated with Ad administration. Coating particles in cationic liposomes 42, 43 has been attempted in order to mask the virion capsid motifs, leading to an enhanced safety profile. 44 Improvements in vector design and delivery methods have increased efficiency of transduction and transgene expression, reducing the therapeutic dose requirements (thereby decreasing acute toxicity). 7 Recently, transient Kupffer cell depletion or blockade has been proposed as a strategy to improve expression levels from low doses of reporter vector, by eliminating phagocytic vector engulfment. 45, 46 However, clinical application of Kupffer cell-depleting agents might be hampered by their side effects. 47, 48 Activated Kupffer cells are the main source of the membrane-bound TNFa precursor, which is processed to produce the mature, secreted cytokine. 49 This further implicates TNFa as a candidate to modulate the early immune response.
Modulation of
The safety of systemic administration of Ad vectors has been under scrutiny since the death of a young patient enrolled in a gene therapy trial for the treatment of ornithine transcarbamylase deficiency. 50 This event has been attributed to strong activation of the innate immune system (characterized by inflammation, coagulopathy and respiratory distress) as a result of intrahepatic arterial injection of an E1/E4-deleted Ad. 51 The clinical course was particularly notable for the dramatic elevation of IL-6 which was sustained up until the time of death. 50 The relationship between vector dose and hepatic transduction is not linear and therefore the window between therapeutic dose and toxic dose might be narrow. Hence, a prerequisite goal is to reduce Adinduced acute toxicity while increasing the therapeutic efficacy of the vector. Substantial pharmacogenetic variation exists in the human population, hindering accurate determination of a patient's immune tolerance to Ad vectors. As a result, risk-benefit assessments for many genetic diseases do not support clinical usage of Ad vectors in their current state. 17 Here, we describe a strategy aimed at improving the acute toxicity profile associated with systemic administration of Ad vectors through pharmacological modulation of the TNFa response. Of particular interest, we used a drug approved for clinical use in the US and Europe for the treatment of rheumatoid arthritis and psoriasis. As demonstrated by several clinical trials, Enbrel s (clinical grade huTNFR:Fc) is well tolerated by both adult and pediatric patients. We have demonstrated the usefulness of this drug in reducing the Ad vector-induced acute IL-6 burst and thrombocytopenia, both of which are particularly evident in baboons and humans receiving lethal doses of Ad. 4, 10, 21 Although in our mouse model, anti-TNF-pretreatment never fully restored platelet counts, a partial mitigation of thrombocytopenia might still be clinically relevant in animal models or human patients with predispositions for consumptive coagulopathies. This line of research could logically be extended to Ad-treated nonhuman primates, since huTNFR:Fc is available and would be efficacious in these animal models.
Although some prior studies have failed to find significant TNFa induction in response to Ad administration, [7] [8] [9] [10] experiments using high doses of Ad have in fact found TNFa upregulation. 4, 8 Furthermore, quantification of TNFa in the serum does not reflect the status of membrane-bound TNFa or soluble TNFR production, both of which may influence the magnitude of innate immune responses. 10 This TNFa immunomodulatory pretreatment modality in conjunction with the use of HDV and other strategies for decreasing toxicity will enable continued improvement of therapeutic index that may facilitate human Ad gene therapy clinical trials.
Materials and methods
Adenoviral vectors
The following serotype 5 FGV and HDV were used in this study:
FGV-A/C/b-gal, containing the b-galactosidase transgene driven by the ubiquitous cytomegalovirus (CMV) promoter, was provided by the Vector Core at Baylor College of Medicine (Houston, TX, USA) and was used in Figures 1, 3, 4b-d and 5 . Generation and amplification of FGV-A/C/b-gal was described previously. 4 The FGV AdCA35loxE3, a generous gift from Dr Phil Ng (Baylor College of Medicine), also contains the b-galactosidase transgene driven by the CMV promoter and is described elsewhere.
52 AdCA35loxE3 was used in Figures 2, 4a and 6. The HDV HD28E4LacZ contains the b-galactosidase transgene driven by the CMV promoter and was produced as described elsewhere. 53 Helper-virus contamination in this viral preparation was assessed by Southern blot and PhosporImager analysis and was estimated to be o0.05% as described elsewhere. 53 All Ad vectors were suspended in phosphate-buffered saline for a final injection volume of 200 ml per mouse, and injected into the prewarmed mouse tail vein.
Experimental mice
All experimental groups consist of age-matched female mice with a minimum age of 6 weeks, and each treatment group consisted of five mice. C57BL/6J, TNFa-deficient (B6.129S-Tnf tm1Gkl /J), perforin-deficient (C57BL/6-Pfp tm1Sdz /J), interferon-g-deficient (B6.129S7-Ifng tm1Ts /J), and mast cell-deficient (C57BL/6J-Kit W-v /J) mice are all on the BL/6J background. All mice were purchased from The Jackson Laboratories (Bar Harbor, ME, USA).
Complete blood counts and serum chemistry assays
Blood was drawn from the retro-orbital plexus of mice after sedation via intraperitoneal (i.p.) injection with a rodent anesthetic solution containing ketamine, xylazine and acepromazine. For complete blood counts (CBCs), blood was drawn into ethylenediamine-N, N, N 0 , N 0 -tetraacetic acid-coated tubes (Microvette, Sarstedt, Germany) and analyzed on an Advia 120 Hematology System (Bayer, New York, NY, USA) by the Clinical Pathology Laboratory of the Center for Comparative Medicine at Baylor College of Medicine (Houston, TX, USA). 'Normal' ranges for murine platelets and white blood cells were also obtained from the Advia 120 machine.
To measure transaminases, serum was collected by twice centrifuging whole blood at 8000 r.p.m. for 10 min. Serum levels of ALT and AST, measured in IU/l, were quantified with a Cobas Integra 400 Plus (Roche, Switzerland) by the Clinical Pathology Laboratory of the Center for Comparative Medicine (Houston, TX, USA).
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b-Galactosidase and enzyme-linked immunosorbent assays
To measure b-galactosidase activity, liver homogenate protein concentration was first determined using a micro BCA protein assay reagent kit (Pierce, Rockford, IL, USA). b-Galactosidase activity (measured in IU/mg) of protein-normalized liver samples was then determined using a specific enzyme assay system (Promega, Madison, WI, USA). Serum levels of mouse TNFa, IL-6 and IL-12 were measured using specific ELISAs (BioSource International, Camarillo, CA, USA), according to the manufacturer's instructions.
Anti-TNFa reagents
The purified monoclonal anti-mouse TNFa antibody (XT22) was obtained from Endogen (Woburn, MA, USA) and was injected i.p. at 250 mg/mouse. The soluble TNF receptor linked to the Fc portion of human IgG1, huTNFR:Fc, was kindly provided by Immunex (Seattle, WA, USA) (now Amgen (Thousand Oaks, CA, USA)), and was injected i.p. at 0.4 or 4.0 mg/kg dose.
Human platelet collection and incubation with Ad
Human blood (from drug-free volunteers upon informed consent), 20 ml, was collected into sodium citrate and spun at 700 g for 7 min. The PRP layer was drawn off and platelet number determined by a Coulter Counter. 4.5 Â 10 6 platelets were used for each platelet FACS condition. Platelets were incubated either alone, with 20 000 Ad particles per cell, or with 10 mM calcium ionophore (a positive control) for 20 min at room temperature. These samples were then incubated with fluorescence isothiocyanate-labeled PAC-1 antibody (Becton Dickinson, San Jose, CA, USA) for an additional 20 min at room temperature. Finally, Tris-buffered saline buffer was added up to a final volume of 500 ml. Platelet activation was assessed by FACS analysis of mean fluorescence intensity of PAC-1-bound platelets, and platelet aggregation was monitored by increases in forward scatter and side scatter using an Epics XL machine (Beckman Coulter, CA, USA).
Statistical analysis of the data
Results are expressed as means7standard deviation (s.d.) of each experimental group. Data analysis was performed using the InStat statistical program (GraphPad Software Inc., San Diego, CA, USA). The significance of differences was assessed with a two-tailed Student's t test for unpaired data. A P-value of less than 0.05 was considered significant. *Po0.05.
Abbreviations
Ad, adenovirus; FGV, first-generation adenoviral vector; HDV, helper-dependent adenoviral vector; IL-6, interleukin 6; IL-12, interleukin 12; TNFa, tumor necrosis factor alpha; i.v., intravenous; i.p., intraperitoneal
